Skip to content
Homepage
Author:
PharmAla Biotech
Posted Date:
July 21, 2026
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
PharmAla Biotech
July 21, 2026
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
PharmAla Biotech
May 28, 2026
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
PharmAla Biotech
May 26, 2026
PharmAla Issues Q2 Financial Statements and Grants Options
PharmAla Biotech
May 25, 2026
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders
PharmAla Biotech
April 30, 2026
PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data
PharmAla Biotech
February 23, 2026
PharmAla Announces Changes to Board of Directors
PharmAla Biotech
February 16, 2026
